In this episode of the ISHLT Voices podcast, hosted by Natera, you'll hear transplant cardiologists explore the evolving landscape of post-heart transplant care, zeroing in on the transformative shift from traditional, invasive biopsies to cutting-edge noninvasive molecular diagnostics—particularly cell-free DNA technologies.

Brent Lampert, DO

Medical Director, Transplant Cardiologist
The Ohio State University Wexner Medical Center
Columbus, OH USA

Ajith P. Nair, MD, FACC, FAHA

Associate Professor, Medicine—Cardiology
Texas Heart Institute at Baylor College of Medicine
Houston, TX USA

Drs. Lampert and Nair discuss the clinical promise of tools like Natera's Prospera Heart with Donor Quantity Score (DQS), which not only offer heightened accuracy and earlier detection of graft injury and rejection, but also may empower clinicians to strike a vital balance: preventing rejection without over-immunosuppression.

Real-world insights, compelling case examples, and candid discussions about the challenges of biopsy-based monitoring—and how new technology is reshaping decisions, outcomes, and patient peace of mind—make this a must-listen for anyone intrigued by the future of transplantation medicine.

The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

This episode was created for ISHLT Voices and sponsored by Natera.

In this episode of the ISHLT Voices podcast, hosted by Natera, you'll hear a discussion on the need for noninvasive surveillance options for single lung transplantation and the role that the Prospera Lung donor derived cell free DNA (dd-cfDNA) test can play.

There are inherent, increased risks and challenges associated with management of single lung transplantation over double lung. Monitoring through invasive transbronchial biopsy procedures (TBBx) is often not the best option for these high-risk, frail patients.

In this podcast, notable transplant pulmonologists Drs. Rosenheck and Arunachalam highlight the need in the single lung population for noninvasive surveillance options. The Prospera Lung donor derived cell free DNA (dd-cfDNA) test has been validated in single and double lung transplants with emerging data in support of clinical utility. The expert speakers also discuss the recently published data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.

Justin Rosenheck, DO
Assistant Professor of Internal Medicine
Ohio State University | Columbus, OH USA

Ambalavanan Arunachalam, MD
Assistant Professor, Medicine (Pulmonary and Critical Care)
Northwestern Medicine | Chicago, IL USA

The content of this podcast was developed entirely by ISHLT's industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

In this episode of the ISHLT Voices podcast, hosted by Kamada, you'll hear a discussion on the utilization of Cytomegalovirus Immune Globulin (CMV IgG) in solid organ transplantation (SOT).

First, a focused overview of CMV IgG, including what they are, how they are made, and their role in SOT. The experts describe the differences between hyperimmune globulins like CMV IgG and standard immune globulins (IVIG). Then, enjoy a discussion from the experts on two recently presented poster highlighting CMV IgG use in lung transplantation and the need for new emerging data.